MetaCap

Apimeds Pharmaceuticals US (APUS) vs Kiora Pharmaceuticals (KPRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kiora Pharmaceuticals (KPRX) has outperformed Apimeds Pharmaceuticals US (APUS) over the past year, losing 61.5% versus a loss of 93.0%. Kiora Pharmaceuticals is the larger company by market cap ($3.2 million vs $3.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APUS-92.98%KPRX-61.49%
+60%-20%-100%
Nov 21, 20251 yearNov 20, 2026
APUS-92.73%KPRX-77.84%
+53%-23%-100%
May 5, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APUS versus KPRX key metrics
MetricAPUSKPRX
Share price$1.60$0.7202
Market cap$2.96M$3.19M
1-day change-8.05%-12.28%
YTD return-90.24%-63.44%
1-year return-92.98%-61.49%
5-year return—-99.87%
EPS (TTM)$-12.69$-2.72
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-6.00M$-10.84M
52-week high$59.70$2.91
52-week low$1.51$0.72
Distance from 52-week high-97.32%-75.25%
Analyst consensus—none
Avg. price target upside—+1566.20%
Average volume3.73M35.23K
Shares outstanding1.85M4.42M
Employees—13
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KPRX has outperformed APUS by 31.5 percentage points over the past year.

About Apimeds Pharmaceuticals US

APUS stock →

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure.

Health Care · Biotechnology: Pharmaceutical Preparations

About Kiora Pharmaceuticals

KPRX stock →

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

APUS vs KPRX FAQ

Which is bigger, Apimeds Pharmaceuticals US or Kiora Pharmaceuticals?

Kiora Pharmaceuticals (KPRX) is larger, with a market capitalization of $3.19M compared with $2.96M for Apimeds Pharmaceuticals US (APUS).

Which stock has performed better over the past year, APUS or KPRX?

KPRX returned -61.49% over the past 12 months, compared with -92.98% for APUS (price return, excluding dividends). Past performance does not predict future results.

Are Apimeds Pharmaceuticals US and Kiora Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons